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Background: No biological marker is currently available for evaluating pulmonary involvement
and/or for monitoring the clinical course of sarcoidosis. The present pilot study focused on
possible relationships between circulating plasma levels of surfactant protein type B (SP-B)
and plasma receptor for advanced glycation end products (RAGE) and lung function abnormal-
ities in patients with pulmonary sarcoidosis, since both SP-B and RAGE have been previously
suggested as lung injury markers. The plasmatic levels of these two proteins were also inves-
tigated with respect to functional capacity, as assessed by a cardiopulmonary exercise test
(CPET).
Methods: Thirty pulmonary sarcoidosis outpatients and fifteen volunteers (Control Group) un-
derwent lung function tests and CPET. Resting SP-B and RAGE plasma levels were also deter-
mined. Patients were then categorized according to the severity of their pulmonary
involvement, as assessed in terms of lung diffusion for carbon monoxide (DLCO) values.
Results: Group B showed SP-B levels higher and RAGE levels lower than Group A and Control
Group (p < 0.01). Group A showed lower RAGE levels than Control Group (p < 0.01), whereas
SP-B levels did not differ between these two groups. A significant univariate relationship wasiologico Monzino, IRCCS, Via Parea 4, 20138 Milan, Italy. Tel.: þ39 02 58002586; fax: þ39 02 58002283.
stoni@unimi.it, piergiuseppe.agostoni@ccfm.it (P. Agostoni).
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1618 D. Magrı` et al.found between both SP-B and RAGE and several lung function data, particularly with DLCO (SP-B
Vs DLCO: r: 0.437, p Z 0.016; RAGE Vs DLCO: r: 0.451, p Z 0.012).
Conclusions: Circulating plasma levels of SP-B and RAGE showed an opposite behavior in pa-
tients with pulmonary sarcoidosis. SP-B values are directly related to alveolar unit damage,
supporting a possible role of SP-B as a marker of disease severity in these patients. Differently,
RAGE decreases in severe sarcoidosis, suggesting more complex underlying mechanisms.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Total lung diffusion for carbon monoxide (DLCO) is among
the strongest functional parameters correlated with
severity and prognosis in patients with pulmonary sarcoid-
osis [1,2]. Indeed, lung diffusion abnormality reflects the
extent of the impairment of the entire gas exchange area,
which can occur either in terms of capillary volume
decrease or in terms of alveolar-capillary barrier thickness
and/or ventilation-perfusion mismatch increase [2e5]. In
pulmonary sarcoidosis, however, a broad spectrum of his-
topathologic abnormalities have been proposed to explain
the typical DLCO reduction, such as scattered granuloma-
tous parenchymal involvement, hemosiderosis, pulmonary
vein/artery granulomas, as far as pulmonary fibrosis
[3,4,6,7].
Notwithstanding the above-mentioned structural lung
damages, no plasmatic biomarker is currently reliable in
evaluating pulmonary involvement and/or in monitoring the
clinical course of pulmonary sarcoidosis [8]. In this context,
both surfactant protein type B (SP-B) and plasma receptor
for advanced glycation end products (RAGE) appear prom-
ising. Indeed, SP-B is one of the four surfactant proteins
with a specific function in stabilizing the alveolar surfactant
and, under physiological conditions, it is mainly confined
into the alveolar space, being almost undetectable in
bloodstream [9,10]. Conversely, in case of different path-
ological conditions characterized by an alveolar damage, its
circulating plasma levels have been shown to increase
[11e14]. On the other hand, RAGE belongs to the immu-
noglobulin superfamily, and its role in lung physiology still
remains far from being elucidated. In fact, besides being
recognized as a marker of acute lung injury [13e15], RAGE
has also been suggested as a protective protein against the
mechanisms underlying pulmonary fibrosis in different
pulmonary diseases [16e18]. As a consequence, albeit with
possibly different pathophysiological meanings, both
circulating plasma levels of SP-B and RAGE might be useful
in staging and managing patients with pulmonary
sarcoidosis.
Therefore, the aim of this single-center pilot study was
to investigate the relationships between circulating plasma
levels of SP-B and RAGE and lung function abnormalities in
patients with pulmonary sarcoidosis. Moreover, because
resting lung function measurements might only partially
reflect the real extent of lung impairment in pulmonary
sarcoidosis [19,20], we also investigated the possible rela-
tionship between the plasmatic levels of these two proteins
and exercise behavior, as assessed by a cardiopulmonary
exercise test.Methods
Study population
We evaluated 37 Caucasian outpatients with a biopsy
specimen-proven sarcoidosis, who were regularly followed
by a dedicated Respiratory Facility (pneumological ambu-
latory) of the Azienda Ospedaliera Sant’Andrea, “Sapienza”
University of Rome. A cohort of eighteen apparently
healthy volunteers, well-matched with the cases as for
general characteristics, acted as controls.
All sarcoidosis patients had had chest radiographs and/
or thoracic high-resolution computed tomography within a
6-month period, and they were accordingly classified [21].
Only patients with radiological evidence of pulmonary
involvement, namely those with stage 2e4, were enrolled
in the current study, whereas those with stage 0 and 1
were excluded. Other exclusion criteria were current
smoke habit, moderate to severe renal failure, moderate
to severe anemia, systemic or pulmonary arterial hyper-
tension, diabetes, known coronary artery disease, echo-
cardiographic evidence of left ventricular (LV) wall-motion
abnormalities, depressed LV ejection fraction
(LVEF < 55%), valvular disease, or LV hypertrophy. Subjects
who were receiving any cardiovascular therapy were also
excluded.
All participants gave written informed consent to the
procedures, and the study was approved by the internal
review board of S. Andrea Hospital e “Sapienza” University
of Rome (protocol number 0049-2010). Each subject who
fulfilled the initial inclusion criteria underwent a full
pneumological and cardiological clinical assessment in two
sessions within the same day.Specimen handling and assays
Immediately before starting clinical sessions, after lying
down for 15 min, each participant underwent a venous
blood sample drawing. Blood was collected in Vacutainer
tubes containing citrate 0.129 mol/L, centrifuged at
3000 rpm at 4 C, and plasma was stored at 80 C for blind
batch analysis.
The quantitative analysis of SP-B levels was performed
by an enzyme-linked immunosorbent assay (Uscn Life Sci-
ence Inc., Wuhan, China), as previously described [13,14].
The concentration of SP-B in the samples was then deter-
mined by comparing the absorbance of the samples to the
standard curve and expressed as ng SP-B/mL. The limit of
sensitivity was 1.95 ng/mL. Inter-assay coefficient of
SP-B and RAGE in pulmonary sarcoidosis 1619variation was 11.6  2.1%. Intra-assay coefficient of varia-
tion was 7.9  1.5%.
Plasma levels of RAGE were determined using a
commercially available enzyme-linked immunoassay kit
(R&D Systems, Minneapolis, MN, USA) according to the
manufacturer’s protocol [13,14]. Measurements were per-
formed in duplicate and the results were averaged. The
intra-assay and inter-assay coefficients of variation were
<6 and <8%, respectively.
Resting pulmonary function evaluation
Participants were evaluated using standard resting pulmo-
nary function tests (Quark PFT, Cosmed, Rome, Italy).
Forced expiratory volume in 1 s (FEV1), forced vital ca-
pacity (FVC), and their ratios (FEV1/FVC) were obtained
according to the standard criteria [22]. Resting arterial
blood gas levels, namely arterial O2 (PaO2) and carbon di-
oxide (PaCO2) partial pressure, and arterial O2 saturation
(SaO2) were measured. DLCO was measured with the single-
breath method, and its value was corrected for hemoglobin
concentrations according to Cotes’ formula [23].
Doppler echocardiography evaluation
All participants underwent a conventional M-mode and two-
dimensional echocardiography Doppler evaluation (Acuson
Sequoia C512, Siemens Medical Solution, CA e USA). LV
mass index (LVMI) was calculated with the standard for-
mula: LVMI Z LV mass divided by height to the power of
2.7. The LVEF was obtained using Simpson’s biplane
methods in two-dimensional echocardiography from the
apical four-chamber view. The tricuspidal annular plane
systolic excursion (TAPSE) was measured in the M-mode by
placing the cursor through the lateral tricuspid annulus in
the apical four-chamber view. Pulmonary systolic artery
pressure (PASP) was indirectly obtained by adding the mean
right atrial pressure to the peak systolic pressure gradient
of tricuspid regurgitant flow [24]. Standard echocardio-
graphic views were analyzed by a single expert physician
blind to the results of subjects’ clinical characteristics, and
they were obtained according to the recommendations by
the American Society of Echocardiography [25].
Cardiopulmonary exercise test (CPET)
A maximal symptom-limited CPET was performed on an
electronically braked cycloergometer (Ergoline-800, Mor-
tara, Bologna, Italy), the subject wearing a nose clip and
breathing through a mass flow sensor (Quark PFT, Cosmed,
Rome, Italy) connected to a saliva trap. A personalized
ramp exercise protocol was performed, aiming at a test
duration of 10  2 min [26]. The exercise was preceded by
few minutes of resting breath-by-breath gas exchange
monitoring and by a 3-min unloaded warm-up. CPET was
self-terminated by the subjects when they claimed that
they had achieved maximal effort. However, we considered
maximal effort as achieved if the respiratory exchange
ratio (RER) was above 1.05.
Predicted values for pVO2 were calculated according to
the standard formula [27]. The anaerobic threshold wasidentified through a V-slope analysis of VO2 and carbon di-
oxide production (VCO2), and it was confirmed through
specific behavior of O2 (VE/VO2) and CO2 (VE/VCO2) venti-
latory equivalents and end-tidal pressure of O2 and CO2.
The end of the isocapnic buffering period was identified
when VE/VCO2 increased and end-tidal pressure of CO2
decreased. The relation between VE and VCO2 (VE/VCO2
slope) was calculated as the slope of the linear relationship
between VE and VCO2 from 1 min after the beginning of
loaded exercise to the end of the isocapnic buffering period
[28e30]. A 12-lead ECG, arterial systemic blood pressure,
and arterial O2 saturation (integrated pulse-oxymeter)
were also recorded at baseline and during effort. All CPET
were executed and analyzed by two physicians blinded to
patients’ clinical features.
Statistical analysis
An extension of the ShapiroeWilk test of normality was
preliminarily performed. Unless otherwise indicated, all
data are expressed as mean  SD. Statistical comparison
was performed between controls and sarcoidosis patients,
the latter being further subdivided into two subgroups ac-
cording to the severity of their pulmonary involvement
(Group A: DLCO > 33rd percentile; Group B: DLCO  33rd
percentile). Categorical variables were compared with c2
test, while ANOVA followed by Bonferroni post-hoc analysis
was used to compare the general characteristics and other
continuous data between the three study groups. Univari-
ate Pearson analysis was used to disclose, within the entire
sarcoidosis group, possible relationships between pulmo-
nary involvement severity, in terms of DLCO values, and all
the above-mentioned laboratory, pneumological, Doppler
echocardiography and CPET data. A p value <0.05 was
considered as statistically significant. All tests were two-
sided. All data were evaluated with the database
SPSSePC þ (SPSSePC þ Inc., Chicago, IL, USA).
Results
Out of the 57 subjects evaluated, only 30 sarcoidosis pa-
tients and 15 controls met the study inclusion/exclusion
criteria and were actually considered in the present anal-
ysis. Two patients and two control subjects were excluded
due to an exercise test judged as not maximal according to
RER; one patient and one control subject were excluded
due to poor compliance to DLCO measurement techniques;
finally, one patient was excluded due to echocardiographic
evidence of left ventricular disease and another one for
laboratory technical reasons. Diagnosis of sarcoidosis was
proven by the presence of non-caseating, epithelioid-cell
granulomas from mediastinal/peripheral lymph node biopsy
in 16 patients, skin lesion biopsy in 4 patients and bronchial
wall biopsy in the remaining patients.
Within the sarcoidosis group, 10 patients showed DLCO
values lower than 69% of the predicted value (lowest DLCO
tertile) and were included in Group B (stage 2: 1 patient;
stage 3: 2 patients; stage 4: 7 patients); the remaining 20
patients, characterized by DLCO values over the lowest
tertile, constituted Group A (stage 2: 14 patients; stage 3: 6
patients; stage 4: none). At HRCT, available in all patients,
1620 D. Magrı` et al.the occurrence of perilymphatic nodular thickening were
found in almost all patients, areas of ground-glass attenu-
ation in 11 patients (Group A: 3 patients, 15% Vs Group B: 8
patients, 80%) and intralobular interstitial thickening in 16
patients (Group A: 8 patients, 40% Vs Group B: 8 patients,
80%) whereas there were no signs of pulmonary arteries or
venous compression in any case. Sarcoidosis involved at
least one extrapulmonary organ in 11 of the 30 patients
enrolled (skin: 4 patients; liver: 3 patients; joints: 3 pa-
tients; peripheral adenopathy: 4 patients; Group A: 6 pa-
tients, 30% Vs Group B 5 patients, 50%). As regards the
possible previous or current specific treatment, 20 patients
were receiving or had received prednisone (Group A: 13
patients, 65% Vs Group B: 7 patients, 70%), whereas 8 pa-
tients (Group A: 5 patients, 25% Vs Group B: 3 patients, 30%)
had received methotrexate and/or cyclofosfamide treat-
ment more than 6 months before enrolling in the study.
All three study groups were well-matched for age,
gender, body surface area, arterial systemic blood pres-
sure, and hemoglobin concentration, whereas the control
group showed significantly lower values of resting heart
rate than Group A and B. Doppler echocardiography showed
a progressive increase in PASP values from control subjects
to Group A and B. In Group B, TAPSE values were slightly
reduced with respect to controls (Table 1).
As expected, Group B showed the worst pulmonary
function in terms of FVC, FEV1, and DLCO values, while no
difference was found for FEV1/FVC and resting SaO2. Both
Groups A and B showed PaO2 values lower than those of the
control group. At CPET, lower pVO2 values, higher VE/VCO2
values and a more pronounced decrease in SaO2 at peak
exercise were present in Group B. Moreover, VE/VCO2Table 1 Clinical characteristics in healthy controls and in the tw
of pulmonary involvement (DLco values).
Variables Healthy controls (n Z 15)
Age, years 55  8
Male, n (%) 6(40)
Body surface area, m2 1.76  0.14
NYHA class I/II/III, n 15/0/0a,c
Haemoglobin, g/dL 14.0  0.8
Non/ex/current smokers 14/1/0
Radiological stage, II/III/IV e
Time from diagnosis, years e
Systolic blood pressure, mmHg 121  11
Diastolic blood pressure, mmHg 81  7
HR, beats/min 78  9a,b
LVEF, % 60  4
LVMI, g/m2.7 41  16
TAPSE, mm 25  3c
PASP, mmHg 22  3a,c
Data are expressed as mean  SD or as absolute numbers (percentag
ventricular ejection fraction; LVMI: left ventricular mass index; TAP
graphic pulmonary arterial systolic pressure.
a p < 0.05 Healthy controls Vs Group A.
b p < 0.05 Healthy controls Vs Group B.
c p < 0.001 Healthy controls and/or Group A Vs Group B.
d p < 0.05 Group A Vs Group B.values were also significantly higher in Group A than in
healthy controls (Table 2).
Circulating plasma levels of SP-B were significantly
higher in Group B than in healthy controls and Group A.
Conversely, plasmatic RAGE concentrations were progres-
sively lower from controls to Group A and Group B (Table 2,
Fig. 1).
Univariate analysis disclosed a significant relationship of
both SP-B and RAGE with several resting lung function and
CPET data (Table 3). Circulating plasma levels of SP-B were
related to DLCO (Fig. 1), pVO2, VE/VCO2 slope, and DSaO2.
Circulating plasma levels of RAGE were related to DLCO
(Fig. 1), FVC, FEV1, pVO2, and DSaO2.Discussion
Our findings, albeit preliminary and obtained in a small
cohort, showed for the first time a significant relationship
between circulating plasma levels of SP-B and RAGE and
lung function impairment in patients with pulmonary
sarcoidosis. Interestingly, a relationship between DLCO and
plasma concentration of SP-B and RAGE was observed.
SP-B is one of the four surfactant proteins, and its specific
function is to stabilize the alveolar surfactant. SP-B is
exclusively synthesized in type II alveolar cells as an imma-
ture form that undergoes several proteolytic processes
leading to an active form, namely the one evaluated in this
study [9,10]. Under physiological conditions, this small
peptide has a relevant gradient across the alveolar-capillary
membrane, so that only a low SP-B concentration is found in
the bloodstream, whereas, in case of damaged alveolar unit,o subgroups of sarcoidosis patients according to the severity
Sarcoidosis patients P-values ANOVA
Group A (n Z 20) Group B (n Z 10)
54  9 55  13 Ns
9(43) 4(40) Ns
1.88  0.24 1.86  0.19 Ns
17/2/1c,d 0/6/4 0.019
14.1  0.9 13.8  1.11 Ns
18/2/0 9/1/0 Ns
14/6/0 1/2/7 e
6.9  5.3 5.9  3.0 e
117  9 114  6 Ns
75  6 74  8 Ns
84  7 89  8 0.023
61  2 62  5 Ns
43  12 38  8 Ns
22  3 19  4 0.022
29  6c,d 32  7 0.001
e). NYHA: New York Heart Association; HR: heart rate; LVEF: left
SE: tricuspid annular plane systolic excursion; PASP: echocardio-
Table 2 Resting pulmonary function, CPET and laboratory data in healthy controls and in the two subgroups of sarcoidosis
patients according to pulmonary involvement severity (DLco values).
Variables Healthy controls (n Z 15) Sarcoidosis patients P-values ANOVA
Group A (n Z 20) Group B (n Z 10)
FVC, % predicted 107  11c 103  16c 69  17 0.000
FEV1, % predicted 103  17c 103  17c 67  17 0.000
FEV1/FVC, % predicted 101  8 99  7 95  12 Ns
DLCO, % predicted 93  7c 91  12c 50  10 0.000
Resting PaO2, mm Hg 90  4a,c 83  10 80  9 0.024
Resting SaO2, mm Hg 98  1 96  1 96  1 Ns
pVO2, ml/kg 25.1  6.6a,c 20.8  3.3c 14.3  3.2 0.000
pVO2, % predicted 98  11a,c 86  9c 58  8 0.000
VE/VCO2 slope 27.4  3.0a,c 29.1  3.7c 40.6  5.5 0.000
R.E.R. 1.19  0.06a,c 1.11  0.05 1.13  0.08 0.001
DSaO2, % 0.6  0.5c 1.1  0.9c 6.1  2.8 0.000
SP-B, ng/mL 3254  1295b 3345  1218d 5277  2293 0.004
RAGE, pg/mL 1316  274a,c 974  341d 484  165 0.000
Data are expressed as mean  SD or as absolute numbers (percentage). FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity;
DLCO: total lung diffusion for carbon monoxide; PaO2: arterial oxygen pressure; SaO2: arterial oxygen saturation; pVO2: peak oxygen
uptake; VE/VCO2 slope: relation between ventilation and carbon dioxide production; R.E.R.: respiratory exchange ratio; DSaO2: (peak-
resting SaO2); SP-B: surfactant protein type B; RAGE: plasma receptor for advanced glycation end products.
a p < 0.05 Healthy controls Vs Group A.
b p < 0.05 Healthy controls Vs Group B.
c p < 0.001 Healthy controls and/or Group A Vs Group B.
d p < 0.05 Group A Vs Group B.
SP-B and RAGE in pulmonary sarcoidosis 1621such as in case of acute pulmonary edema or lung injury, a
high SP-B plasmatic concentration has been detected
[11,31,32]. Accordingly, a possible role of SP-B as biomarker
of alveolar-capillary barrier damage in patients undergoing
transient mechanical ventilation [12,13] and in patients with
stable chronic heart failure has also been proposed [14].
Similarly, in thepresent study, ahigher plasmaconcentration
of SP-B was detected in the sarcoidosis patients with the
worst DLCO, suggesting the hypothesis that lung parenchymal
and vascular destructive granulomatous lesions may result in
an augmented SP-B leakage from the alveoli into the blood-
stream. Indeed, DLCO is strongly related to damages of
alveolar-capillary unit, such as a decrease in capillary vol-
ume, or an increase in barrier thickness and/or in the
ventilation-perfusion mismatch [2,4e7]. Accordingly, VE/
VCO2 slope and DSaO2 values were significantly increased in
the patients with the most impaired lung function, and they
significantly correlatedwith circulating plasma levels of SP-B
[14,29,33].
The observed behavior of RAGE underlines a different,
much less clear pathophysiological meaning as compared to
SP-B. RAGE belongs to the immunoglobulin superfamily and,
whilst it is typically expressed at low levels under normal
physiological conditions in most tissues, it exhibits a high
basal level expression in lungs [16,17]. RAGE and SP-B have
been previously suggested as possible biomarkers of lung
injury [15,34]. Indeed, we showed an almost parallel in-
crease in both the plasmatic levels of RAGE and SP-B in
patients undergoing major surgery, and this finding was
interpreted as a direct consequence of an alveolar damage
due to the mechanical ventilation [13,14]. Conversely in a
recent study, conducted on a cohort of healthy subjects
with acute high altitude exposure, neither plasma SP-B norRAGE levels increase have been found, this datum implying
only an interstitial fluid overload rather than an acute
damage in the alveolar cell barrier [35]. In the present
study on sarcoidosis patients, the lowest RAGE values were
found in those with the worst lung diffusion. As a matter of
fact, a pivotal role of RAGE in protecting against the
mechanisms underlying pulmonary fibrosis onset and pro-
gression has been suggested, given that it is involved in
modulating the adhesion of alveolar epithelial cells to the
basement membrane [16,17]. Indeed, fibrosis-like alter-
ations have been found in the lungs of RAGE-deficient mice
[18,36], and the presence of a significant inflammatory-
induced RAGE down-regulation has been demonstrated in
idiopathic pulmonary fibrosis [36,37]. Accordingly, given
that the group with the lowest DLco values included a large
percentage of patients with pulmonary fibrosis, it might be
hypothesized that low RAGE values might be a cause, rather
than a consequence, of the observed lung function
impairment. However, evidence of a role of RAGE in pro-
moting fibrosis has been supplied as well [38,39]. There-
fore, it might be also speculated that our data simply
reflect a loss of alveolar type I epithelial cells, primary
expressers of RAGE. Other observations of the present
study underlined a much less clear behavior of RAGE in
patients with chronic lung damage such as those affected
by sarcoidosis. Indeed, we reported a correlation of RAGE
with DLCO and with DSaO2 during exercise but, unexpect-
edly and differently from SP-B, not with VE/VCO2 slope, a
marker of ventilation/perfusion mismatch during exercise.
We presently do not have an explanation of the bulk of our
findings, which, however, suggest that RAGE is not a direct
marker of lung damage in sarcoidosis patients. Indeed,
whilst RAGE mirrors alveolar unit damage in case of acute
Figure 1 Left panels: differences in circulating Surfactant Protein type B (SP-B) (upper panel) and RAGE (lower panel) between
healthy subjects (Controls) and patients with pulmonary sarcoidosis with lung diffusion for carbon monoxide (DLCO) values higher
(Group A) and equal/lower (Group B) than the lowest tertile. In the box plots, the central line represents the median distribution.
Each box spans from 25th to 75th percentile points, and error bars extend from 10th to 90th percentile points. Right panels:
Pearson univariate relationship within the entire sarcoidosis sample between SP-B (upper panel) and RAGE (lower panel) versus
DLCO (upper panel).
1622 D. Magrı` et al.lung injury where the cell lysis leads to an increased
leakage into the bloodstream, this seems not the case
during chronic lung diseases, where its plasmatic concen-
tration might be low due to a down-regulation and/or to an
exhaustion of RAGE production. Furthermore, given that
RAGE is known to be also secreted by monocyte/macro-
phage cells along the inflammatory cascade [40], it might
be hypothesized that RAGE could increase in a mannerTable 3 Relationship (univariate “r” values) between laboratory
in the entire sarcoidosis study sample (n: 30).
Variables DLCO FVC FEV1
FVC 0.696b e e
FEV1 0.707
a 0.905a e
pVO2 0.754
a 0.747a 0.714a
VE/VCO2 slope 0.847a 0.560b 0.534
DSaO2 0.797a 0.608a 0.648a
SP-B 0.437c Ns Ns
RAGE 0.451c 0.502b 0.429c
For abbreviations see Table 1.
a p < 0.001.
b p < 0.01.
c p < 0.05.proportional to number of active granulomas and, most
likely, decrease when fibrosis replaces them. The actual
study design clearly enables us only to speculate about
mechanisms underlying our findings because of the small
sample enrolled, the lack of patients without pulmonary
involvement (stage 1) and, above all, because of we did not
obtain seriate plasma RAGE dosages for each patient at
different disease-steps., main pneumological and cardiopulmonary exercise test data
pVO2 VE/VCO2 slope DSaO2 SP-B
e e e e
e e e e
e e e e
0.688a e e e
0.700a 0.682a e e
0.356c 0.450c 0.361c e
0.563b Ns 0.531b Ns
SP-B and RAGE in pulmonary sarcoidosis 1623In conclusion, this is the first study where circulating
plasma levels of SP-B and RAGE were measured in patients
with pulmonary sarcoidosis. We showed a significant rela-
tionship of the plasmatic levels of these two proteins with
several lung function measurements routinely adopted in
the clinical management of this setting of patients. Longi-
tudinal studies in larger study samples are needed to sub-
stantiate our brief report, mainly concerning a possible
utility of plasma SP-B levels in the daily clinical manage-
ment as well as its hypothetical prognostic role in patients
with sarcoidosis. Differently, our data about RAGE behavior
call for more dedicated experimental studies in order to
elucidate its role in this setting of patient, mainly focusing
on the relationship between plasma RAGE levels with the
effective RAGE expression in the lung.Conflict of interest
There are no conflicts of interest in connection with the
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